NCT04148963View on ClinicalTrials.gov

A Study of Staccato Loxapine (ADASUVE®) for Inhalation

PHASE3UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

May 1, 2020

Study Completion Date

August 1, 2020

Conditions
Psychomotor AgitationSchizophreniaBipolar Disorder
Interventions
DRUG

Inhaled loxapine

Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours

DRUG

Inhaled placebo

Inhaled placebo, may repeat x 1 or 2 after 2 hours

Sponsors
All Listed Sponsors
lead

Lee's Pharmaceutical Limited

INDUSTRY